Joshua Yang
Glyphic Biotechnologies
September 22
Although decoding the human genome through the invention of DNA sequencing has ushered in a new era of biomedical sciences, this blueprint is not enough. We are defined by more than our genes: to understand the human body, we must understand the proteins that actually perform our day-to-day functions--and malfunctions. Glyphic Biotechnologies is decoding the human proteome through full coverage, de novo protein sequencing at single molecule resolutions, advancing beyond the decades old technologies based on mass spectrometry and ELISAs.This platform will enable the development of novel therapeutics and diagnostics and, ultimately, a deeper understanding of human biology.
September 29
Although decoding the human genome through the invention of DNA sequencing has ushered in a new era of biomedical sciences, this blueprint is not enough. We are defined by more than our genes: to understand the human body, we must understand the proteins that actually perform our day-to-day functions--and malfunctions. Glyphic Biotechnologies is decoding the human proteome through full coverage, de novo protein sequencing at single molecule resolutions, advancing beyond the decades old technologies based on mass spectrometry and ELISAs. This platform will enable the development of novel therapeutics and diagnostics and, ultimately, a deeper understanding of human biology.